. 2017 Nov 16;12(11):e0188190. doi: 10.1371/journal.pone.0188190

Table 1. Demographic, clinical and virological characteristics of individual patients.

Case	Blood Type	Age	Etiology	Hepatitis B history (years)	MELD	Pre-LT			At the start of vaccination				Anti-HBs titer (IU/L)
Case	Blood Type	Age	Etiology	Hepatitis B history (years)	MELD	HBsAg	Anti-HBs	HBV-DNA	Interval from LT (days)	BMI	Immuno- suppression	NAs	Before vaccine	End of vaccine	Last f/u
1	O	55	HCC+BLC	23	10	+^*	-^*	2.28^*10⁴	514	27.68	TC+SR	ETV	53.76	29.78	26.58
2	O	40	BLC	4	19	0.02	0	2.6^*10³	1607	23.51	SR	ETV	1.04	52.38	72.77
3	A	48	B-FHF	1	NA	+	-	NA	1441	29.27	TC	ADV	31.11	26.19	24.13
4	B	43	BLC	23	3	250	0	6.07^*10⁵	686	21.22	TC+MMF	ADV	45.84	57.13	50.19
5	A	53	HCC+BLC	23	8	250	1.52	NA	563	21.80	TC+MMF	ETV	4.87	17.18	16.64
6	A	26	B-FHF	3	23	0.21	29.3	8.64^*10²	482	26.30	TC+MMF	ETV	7.70	4.98	9.05
7	O	53	HCC+BLC	23	24	+	-	9.75^*10⁶	3218	21.94	TC	LAM	19.87	73.04	53.95
8	A	34	BLC	13	14	0.39	0	NA	1750	24.22	TC	LAM	48.40	13.56	7.81
9	O	59	BLC	13	21	1.07	0	NA	2756	19.10	TC+MMF	LAM	30.96	46.31	23.05
10	A	64	HCC+BLC	1	4	1.23	0	<100	921	27.22	TC+MMF	ADV	4.89	1.89	2.69
11	O	37	BLC	14	24	+	-	<100	4894	21.97	CyA	LAM	10.63	10.6	13.17
12	O	46	HCC+BLC	23	6	+	-	3.38^*10³	608	27.36	SR	ETV	15.38	45.48	53.16
13	O	48	HCC+BLC	6	22	18.21	0	NA	726	29.41	TC+MMF	LAM	26.08	33.48	44.79
14	A	59	HCC	3	14	250	0	9.57^*10³	610	22.41	TC+MMF	ADV	0.10	167.51	113.51
15	B	44	BLC	8	22	0.02	0	NA	1307	20.55	TC+MMF	ETV	9.13	13.77	36.17
16	O	36	BLC	5	19	250	0	1.96^*10³	633	22.65	TC+MMF	ADV	30.70	26.94	33.25
17	A	62	HCC+BLC	20	19	0.01	0	2.18^*10⁷	390	20.90	SR+CyA	ETV	21.62	16.91	21.62
18	A	60	BLC	10	11	250	0	<100	790	24.44	TC+MMF	ETV	32.59	30.5	56.49
19	B	38	HCC	3	8	250	0.09	<100	941	22.66	TC+MMF	ETV	0.00	11.95	0.35
20	O	42	BLC	13	NA	0.02	0.35	NA	1575	23.81	TC+MMF	LAM	13.98	10.46	10.57
21	O	37	B-FHF	13	25	250	0	NA	1532	19.84	TC+MMF	ETV	15.04	19.18	27.67
22	B	61	BLC	1	10	90.28	14.37	3.35^*10³	945	26.89	SR	ETV	14.14	15.45	9.74
23	O	57	BLC	5	14	250	0.21	6.95^*10⁶	394	24.80	TC+MMF	ETV	36.87	19.58	7.536
24	A	42	HCC	7	3	250	0.42	1.39^*10³	972	19.96	TC+MMF	LAM	15.36	14.55	14.55
25	B	47	HCC+BLC	10	7	250	0.26	<100	397	26.30	TC+MMF	ETV	17.86	15.83	11.76
26	B	39	B-FHF	7	26	250	0.51	7.14^*10⁷	501	26.17	TC+MMF	ETV	26.12	28.38	12.85
27	AB	56	HCC+BLC	33	14	114.16	1.42	NA	1853	24.22	TC	ADV	2.43	0.68	0.68

*, results of qualitative detection from primary hospital.

B-FHF, hepatitis B related fulminant hepatic failure; BLC, hepatitis B related liver cirrhosis; HCC, hepatocellular carcinoma; NAs, nucleos(t)ide analogues; LAM, lamivudine; ADV, adefovir dipivoxyl; ETV, entecavir; TC, tacrolimus; SR, sirolimus; MMF, mycophenolate mofetil; CyA, cyclosporine A; f/u, follow-up; NA, not applicable.